Treatment of murine immune complex glomerulonephritis with prostaglandin E2: dose--response of immune complex deposition, antibody synthesis, and glomerular damage.
A model of immune complex glomerulonephritis (ICGN) produced in mice by the daily injection of apoferritin was employed to study the effect of treatment with various doses of prostaglandin E2 (PGE2) on glomerular damage, immune complex deposition, proteinuria, and serum anti-apoferritin antibody. Administration of PGE2, 200 micrograms twice daily, resulted in a significant decrease in glomerular damage and immune complex deposition, prevented the development of proteinuria, and significantly reduced serum levels of anti-apoferritin antibody. PGE2, 100 micrograms twice daily, resulted in a decrease in immune complex deposition as assessed by immunofluorescence microscopy, but this dosage did not significantly alter glomerular damage, proteinuria, or antibody levels. PGE2 dosages of 50 and 25 micrograms twice daily had no effect on any of these parameters. The protective effect of PGE2 on the development of ICGN occurred only at dosages that were associated with decreased anti-apoferritin antibody.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D000936:Antigen-Antibody Complex / Q000032:analysis; D001052:Apoferritins; D015232:Dinoprostone; D004305:Dose-Response Relationship, Drug; D005921:Glomerulonephritis / Q000139:chemically induced / Q000188:drug therapy*; D007074:Immunoglobulin G / Q000032:analysis; D007678:Kidney Glomerulus / Q000187:drug effects* / Q000276:immunology; D008297:Male; D051379:Mice; D011458:Prostaglandins E / Q000627:therapeutic use*; D011507:Proteinuria / Q000175:diagnosis
D000936:Antigen-Antibody Complex; D007074:Immunoglobulin G; D011458:Prostaglandins E; D001052:Apoferritins; D015232:Dinoprostone